Financial

News

Acceleron investors dig their heels in on Merck takeover bid

Activist investors are pushing back against Merck & Co's recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the company.

News

Biogen's Aduhelm rollout goes from bad to worse

Analysts were predicting sales of Biogen's recently approved Alzheimer's therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reve

News

Delta variant keeps Roche diagnostics sales sky high

High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche's diagnostics division, allowing the company to raise its sales forecast for the year.

News

J&J mulls switch from non-profit status for COVID jab

Johnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became available, but is thinking about a possible switch to a standard commercial model

News

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but making it available at no profit had weighed on

News

Final hurdle falls as UK backs AZ's $39bn takeover of Alexio...

The UK's competition regulator has approved AstraZeneca's $39 billion acquisition of US-based drugmaker Alexion, without opting for a broader inquiry into the deal.

Acceleron investors dig their heels in on Merck takeover bid

Biogen's Aduhelm rollout goes from bad to worse

Delta variant keeps Roche diagnostics sales sky high

J&J mulls switch from non-profit status for COVID jab

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

Final hurdle falls as UK backs AZ's $39bn takeover of Alexio...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Financial

Editor's Picks